KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Cash (2017 - 2025)

Historic Change in Cash for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $154.7 million.

  • Amneal Pharmaceuticals' Change in Cash rose 43871.46% to $154.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.1 million, marking a year-over-year increase of 102725.06%. This contributed to the annual value of $19.3 million for FY2024, which is 6976.68% down from last year.
  • Amneal Pharmaceuticals' Change in Cash amounted to $154.7 million in Q3 2025, which was up 43871.46% from $15.3 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Change in Cash registered a high of $154.7 million during Q3 2025, and its lowest value of -$172.7 million during Q2 2021.
  • In the last 5 years, Amneal Pharmaceuticals' Change in Cash had a median value of -$2.3 million in 2022 and averaged -$5.7 million.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 72824.09% in 2023, then skyrocketed by 104500.0% in 2024.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Change in Cash stood at -$53.9 million in 2021, then decreased by 12.59% to -$60.7 million in 2022, then soared by 105.77% to $3.5 million in 2023, then surged by 1045.0% to $40.1 million in 2024, then surged by 286.11% to $154.7 million in 2025.
  • Its Change in Cash was $154.7 million in Q3 2025, compared to $15.3 million in Q2 2025 and -$50.0 million in Q1 2025.